Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glucagon-like peptide-1 analogs mitigate neuroinflammation in Alzheimer's disease by suppressing NLRP2 activation in astrocytes
Mengjun Zhang, Yubin Wu, Ruonan Gao, et al.
Molecular and Cellular Endocrinology (2021) Vol. 542, pp. 111529-111529
Closed Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Pharmacological Research (2022) Vol. 186, pp. 106550-106550
Open Access | Times Cited: 126
Inflammasomes in neurological disorders — mechanisms and therapeutic potential
Kishore Aravind Ravichandran, Michael T. Heneka
Nature Reviews Neurology (2024) Vol. 20, Iss. 2, pp. 67-83
Closed Access | Times Cited: 37
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Haiyang Du, Xiaoyu Meng, Yao Yu, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 53
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Yolanda Diz-Chaves, Zainab Mastoor, Carlos Spuch, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9583-9583
Open Access | Times Cited: 48
Metabolic perspective of astrocyte dysfunction in Alzheimer's disease and type 2 diabetes brains
Zheng Shen, Zhengyang Li, Mengting Yu, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 158, pp. 114206-114206
Open Access | Times Cited: 33
Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus
Maria Chiara Pelle, Isabella Zaffina, Federica Giofrè, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11301-11301
Open Access | Times Cited: 31
Neurodegenerative Diseases: Unraveling the Heterogeneity of Astrocytes
Alberto Santiago-Balmaseda, Annai Aguirre-Orozco, Irais E. Valenzuela-Arzeta, et al.
Cells (2024) Vol. 13, Iss. 11, pp. 921-921
Open Access | Times Cited: 11
Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges
Jacky Tran, Sneh Parekh, Julia Rockcole, et al.
Life Sciences (2024) Vol. 355, pp. 123001-123001
Closed Access | Times Cited: 9
Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
Lívia Cristina Ribeiro Teixeira, Marcelo R. Luizon, Karina Braga Gomes
Receptors (2025) Vol. 4, Iss. 1, pp. 2-2
Open Access | Times Cited: 1
Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer’s disease models: a systematic review and meta-analysis of preclinical studies
Fanjing Kong, Tianyu Wu, Jiyan Dai, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 22
GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models
Vyron Gorgogietas, Bahareh Rajaei, Heeyoung Chae, et al.
Diabetologia (2023) Vol. 66, Iss. 7, pp. 1306-1321
Open Access | Times Cited: 19
Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence
Rae J. Herman, Heath D. Schmidt
Physiology & Behavior (2024) Vol. 281, pp. 114565-114565
Open Access | Times Cited: 6
Glial Cells and Brain Diseases: Inflammasomes as Relevant Pathological Entities
Esperanza Mata‐Martínez, Mauricio Díaz‐Muñoz, Francisco G. Vázquez‐Cuevas
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 20
Exendin‐4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease
Aanchal Verma, Shobhit Chaudhary, Kunal Solanki, et al.
Chemical Biology & Drug Design (2023) Vol. 103, Iss. 1
Closed Access | Times Cited: 11
Astrocytes phenomics as new druggable targets in healthy aging and Alzheimer’s disease progression
Daniele Lana, Filippo Ugolini, Ludovica Iovino, et al.
Frontiers in Cellular Neuroscience (2025) Vol. 18
Open Access
Astrocytes of the hippocampus and responses to periprandial neuroendocrine hormones
Ana L Loera-Lopez, Magen N. Lord, Emily E. Noble
Physiology & Behavior (2025), pp. 114913-114913
Closed Access
Incretin-based therapeutics for the treatment of neurodegenerative diseases
Anika Vear, Michael T. Heneka, Christoffer Clemmensen
Nature Metabolism (2025)
Closed Access
Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders
Hezekiah C T Au, Rex Pui Kin Lam, Poh Khuen Lim, et al.
Neuroscience & Biobehavioral Reviews (2025), pp. 106159-106159
Open Access
Regulation of NLRPs by reactive oxygen species: A story of crosstalk
Bjoern Ziehr, Justin A. MacDonald
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2024) Vol. 1871, Iss. 8, pp. 119823-119823
Open Access | Times Cited: 3
Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP/PS1/tau mice
Zhaojun Wang, Wei-Na Han, Shi-Fan Chai, et al.
Neuroscience (2024) Vol. 563, pp. 222-234
Closed Access | Times Cited: 3
NLRP2 in health and disease
Tongtong Zhang, Fei Xing, Mingcui Qu, et al.
Immunology (2023) Vol. 171, Iss. 2, pp. 170-180
Open Access | Times Cited: 8
GLP-1/Sigma/RAGE receptors: An evolving picture of Alzheimer's disease pathology and treatment
Neha Neha, Zitin Wali, Pinky Pinky, et al.
Ageing Research Reviews (2023) Vol. 93, pp. 102134-102134
Closed Access | Times Cited: 8
“Other Than NLRP3” Inflammasomes: Multiple Roles in Brain Disease
Anna Chiarini, Ubaldo Armato, Li Gui, et al.
The Neuroscientist (2022) Vol. 30, Iss. 1, pp. 23-48
Closed Access | Times Cited: 11
Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration
Katherine O. Kopp, Yazhou Li, Elliot J. Glotfelty, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 872-872
Open Access | Times Cited: 2
Role of NLRP3 Inflammasomes in Neurodegenerative Diseases
Nagihan Demirtaş, Büşra Şahin Mazlumoğlu, Şaziye Sezin Palabıyık Yücelik
Eurasian Journal of Medicine (2024) Vol. 55, Iss. S1, pp. 98-105
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top